Fujian Medical University Union Hospital
Fujian Medical University Union Hospital
Fuzhou, China23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07284849 | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | LGI1 Autoimmune Encephalitis; NMDAR Autoimmune Encephalitis | Active, not recruiting | Phase 3 | 2026-10-08 | NCT05503264 | |
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | HER2-positive Breast Cancer | Recruiting | Phase 2 / Phase 3 | 2026-10-06 | NCT07413939 | |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 3 | 2026-10-06 | NCT07174310 | |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-09-25 | NCT07169578 | |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06319820 | |
| A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05455320 | |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT05327114 | |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT04892173 | |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT03748641 | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06065748 | |
| A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-31 | NCT04538664 | |
| Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-08-24 | NCT07571161 | |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting | Phase 3 | 2026-08-12 | NCT06801834 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-08-10 | NCT06298552 | |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 3 | 2026-08-05 | NCT05171647 | |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-07-27 | NCT04951622 | |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06558279 | |
| A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-06-12 | NCT05673785 | |
| A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study) | Diabetic Peripheral Neuropathic Pain | Active, not recruiting | Not stated | 2026-03-30 | NCT06812117 | |
| Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-10-03 | NCT05840211 | |
| Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2025-04-10 | NCT03936153 | |
| A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-04-10 | NCT03934567 |